Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTOR

New multifunctional drugs that target multiple disease-relevant networks offer a novel approach to the prevention and treatment of many diseases. New synthetic oleanane triterpenoids (SO), such as CDDO (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) and its derivatives, are multifunctional compounds originally developed for the prevention and treatment of inflammation and oxidative stress. However, the protein binding partners and mechanisms of action of these SO are not yet fully understood. Here we characterize the putative target profile of one SO, CDDO-Imidazolide (CDDO-Im), by combining affinity purification with mass spectroscopic proteomic analysis to identify 577 candidate binding proteins in whole cells. This SO pharmaco-interactome consists of a diverse but interconnected set of signaling networks; bioinformatic analysis of the protein interactome identified canonical signaling pathways targeted by the SO, including retinoic acid receptor (RAR), estrogen receptor (ER), insulin receptor (IR), janus kinase/signal transducers and activators of transcription (JAK/STAT), and phosphatase and tensin homolog (PTEN). Pull-down studies then further validated a subset of the putative targets. In addition, we now show for the first time that the mammalian target of rapamycin (mTOR) is a direct target of CDDO-Im. We also show that CDDO-Im blocks insulin-induced activation of this pathway by binding to mTOR and inhibiting its kinase activity. Our basic studies confirm that the SO, CDDO-Im, acts on a protein network to elicit its pharmacological activity.

• Publication year

  2011

• Venue

  PLoS ONE

• Publication date

  2011-07-27

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1371/journal.pone.0022862PMID 21818401PMCID 3144948
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD

  2011cited by this paper
• New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress

  2011cited by this paper
• Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

  2011cited by this paper
• Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and Age-related Macular Degeneration.

  2010cited by this paper
• Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-{kappa}B signaling proteins in colorectal cancer cells.

  2010cited by this paper
• Blueprint for antimicrobial hit discovery targeting metabolic networks

  2010cited by this paper
• mTOR: from growth signal integration to cancer, diabetes and ageing

  2010cited by this paper
• The Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic-acid Methyl Ester Has Potent Anti-diabetic Effects in Diet-induced Diabetic Mice and Leprdb/db Mice*

  2010cited by this paper
• Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.

  2010cited by this paper
• Oleanane Triterpenoid CDDO‐Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro‐survival Akt and mTOR

  2009cited by this paper
• mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific Catalytic Activity and Clarifies Rapamycin Mechanism of Action*

  2009cited by this paper
• The role of the mammalian target of rapamycin (mTOR) in renal disease.

  2009cited by this paper
• The impact of cellular networks on disease comorbidity

  2009cited by this paper
• The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential.

  2009cited by this paper
• Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription

  2009cited by this paper
• A Dynamic Network Approach for the Study of Human Phenotypes

  2009cited by this paper
• Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice.

  2009cited by this paper
• The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice.

  2009cited by this paper
• Synthetic triterpenoids attenuate cytotoxic retinal injury: cross-talk between Nrf2 and PI3K/AKT signaling through inhibition of the lipid phosphatase PTEN.

  2009cited by this paper
• Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice

  2009cited by this paper
• Targeting Nrf2 with the triterpenoid CDDO- imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice

  2009cited by this paper
• Site-Specific mTOR Phosphorylation Promotes mTORC1-Mediated Signaling and Cell Growth

  2009influential reference
• Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268

  2008cited by this paper
• Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

  2008cited by this paper
• The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid-Imidazolide Alters Transforming Growth Factor β-dependent Signaling and Cell Migration by Affecting the Cytoskeleton and the Polarity Complex*

  2008cited by this paper
• Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice.

  2008cited by this paper
• Network pharmacology: the next paradigm in drug discovery.

  2008cited by this paper
• Role of TSC-mTOR pathway in diabetic nephropathy.

  2008cited by this paper
• Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.

  2008cited by this paper
• The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis

  2008cited by this paper
• STRING 8—a global view on proteins and their functional interactions in 630 organisms

  2008cited by this paper
• Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry

  2007cited by this paper
• The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent

  2007cited by this paper
• The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice.

  2007cited by this paper
• Platforms and networks in triterpenoid pharmacology

  2007cited by this paper
• Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer

  2007cited by this paper
• Network pharmacology

  2007cited by this paper
• The Synthetic Triterpenoid CDDO-Imidazolide Suppresses STAT Phosphorylation and Induces Apoptosis in Myeloma and Lung Cancer Cells

  2006cited by this paper
• 2-Cyano-3,12-dioxooleana-1,9(11)-diene-28-oic Acid Disrupts Microtubule Polymerization: A Possible Mechanism Contributing to Apoptosis

  2006cited by this paper
• Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes

  2006influential reference
• AgBase: a functional genomics resource for agriculture

  2006cited by this paper
• Can we rationally design promiscuous drugs?

  2006cited by this paper
• The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

  2006cited by this paper
• Triterpenoid CDDO-Me Blocks the NF-κB Pathway by Direct Inhibition of IKKβ on Cys-179*

  2006cited by this paper
• A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells.

  2006cited by this paper
• Transcriptional regulation via cysteine thiol modification: A novel molecular strategy for chemoprevention and cytoprotection

  2006cited by this paper
• Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole.

  2006cited by this paper
• A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic Cells

  2006cited by this paper
• The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-κB activation through direct inhibition of IκB kinase β

  2006cited by this paper
• Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179.

  2006cited by this paper
• The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta.

  2006cited by this paper
• The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling.

  2005cited by this paper
• Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.

  2005cited by this paper
• Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress.

  2005cited by this paper
• Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action.

  2005cited by this paper
• Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets.

  2004cited by this paper
• The efficiency of multi-target drugs: the network approach might help drug design.

  2004cited by this paper
• The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.

  2004cited by this paper
• The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Caspase-Dependent and -Independent Apoptosis in Acute Myelogenous Leukemia

  2004cited by this paper
• The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo.

  2003cited by this paper
• Cytoscape: a software environment for integrated models of biomolecular interaction networks.

  2003influential reference
• The Novel Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) Potently Enhances Apoptosis Induced by Tumor Necrosis Factor in Human Leukemia Cells*

  2002cited by this paper
• A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production.

  2002cited by this paper
• The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism.

  2001cited by this paper
• Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages.

  2000cited by this paper
• Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.

  2000cited by this paper
• The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism.

  2000cited by this paper
• Direct analysis of protein complexes using mass spectrometry

  1999cited by this paper
• A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity.

  1999cited by this paper
• Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages.

  1998cited by this paper
• Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages.

  1998cited by this paper

• Thirty years of NRF2: advances and therapeutic challenges

  2025cites this paper
• Hepatic cellular stress response pathways exhibit species differences in basal and inducible activity

  2025cites this paper
• Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress

  2025cites this paper
• The Nrf2 Activator CDDO-Imidazole Suppresses Inflammation-Induced Red Blood Cell Alloimmunization

  2025cites this paper
• CDDO-Imidazole regulates RBC alloimmunization to the KEL antigen by activating Nrf2

  2025cites this paper
• Biomarkers of NRF2 signalling: Current status and future challenges

  2024cites this paper
• Discovery of a molecular glue for EGFR degradation

  2024cites this paper
• Compound 7 regulates microglia polarization and attenuates radiation-induced myelopathy via the Nrf2 signaling pathway in vivo and in vitro studies

  2024cites this paper
• Non-electrophilic NRF2 activators promote wound healing in human keratinocytes and diabetic mice and demonstrate selective downstream gene targeting

  2024cites this paper
• Optimization Efforts for Identification of Novel Highly Potent Keap1-Nrf2 Protein-Protein Interaction Inhibitors.

  2024cites this paper
• The synthetic oleanane triterpenoid CDDO‐2P‐Im binds GRP78/BiP to induce unfolded protein response‐mediated apoptosis in myeloma

  2023cites this paper
• Advances in developing noncovalent small molecules targeting Keap1.

  2023cites this paper
• A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)

  2023cites this paper
• Optimization of 3-aminotetrahydrothiophene 1,1-dioxides with improved potency and efficacy as non-electrophilic antioxidant response element (ARE) activators.

  2023cites this paper
• An update of Nrf2 activators and inhibitors in cancer prevention/promotion

  2022cites this paper
• NUCLEAR FACTOR-ERYTHROID-2–RELATED FACTOR REGULATES SYSTEMIC AND PULMONARY BARRIER FUNCTION AND IMMUNE PROGRAMMING AFTER BURN AND INHALATION INJURY

  2022cites this paper
• Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice

  2022cites this paper
• Applications of covalent chemistry in targeted protein degradation.

  2022cites this paper
• Understanding the role of NRF2 signalling in cancer.

  2022cites this paper
• Overlooked and valuable facts to know in the NRF2/KEAP1 field.

  2022cites this paper
• Design, synthesis and biological activity evaluation of a series of bardoxolone methyl prodrugs.

  2022cites this paper
• Chemoproteomic profiling reveals cellular targets of nitro-fatty acids

  2021cites this paper
• Uncovering the anti-angiogenic effect of semisynthetic triterpenoid CDDO-Im on HUVECs by an integrated network pharmacology approach

  2021cites this paper
• Recent Progress in Oleanolic Acid: Structural Modification and Biological Activity.

  2021cites this paper
• Nrf2/Keap1/ARE signaling: Towards specific regulation

  2021cites this paper
• Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation.

  2021cites this paper
• Identification of a new azoreductase driven prodrug from bardoxolone methyl and 5-aminosalicylate for the treatment of colitis in mice.

  2021cites this paper
• Specific Targeting of the Nrf2 Transcription Factor to Prevent Diabetic Kidney Disease Progression by Stimulating the Oxidative Stress Response: A Next-Generation Strategy

  2021cites this paper
• Targeting NRF2 to Treat Cancer.

  2021cites this paper
• The Intricacies of NRF2 Regulation in Cancer.

  2021cites this paper
• The Methyl Ester of 2-Cyano-3,12-Dioxooleana-1,9-Dien-28-Oic Acid Reduces Endometrial Lesions Development by Modulating the NFkB and Nrf2 Pathways

  2021cites this paper
• Discovery and SAR studies of 3-amino-4-(phenylsulfonyl)tetrahydrothiophene 1,1-dioxides as non-electrophilic antioxidant response element (ARE) activators.

  2021cites this paper
• Location, Orientation and Aggregation of Bardoxolone-ME, CDDO-ME, in a Complex Phospholipid Bilayer Membrane

  2020cites this paper
• Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells

  2020cites this paper
• Nrf2: The Master and Captain of Beta Cell Fate.

  2020cites this paper
• Bardoxolone conjugation enables targeted protein degradation of BRD4

  2020cites this paper
• CDDO-Imidazolide Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1.

  2020cites this paper
• Bach1 Inhibition Suppresses Osteoclastogenesis via Reduction of the Signaling via Reactive Oxygen Species by Reinforced Antioxidation

  2020cites this paper
• Role of the transcription factor Nrf2 and redox balance in Parkinson’s disease

  2020cites this paper
• The role of natural products in revealing NRF2 function.

  2020cites this paper
• The Keap1-Nrf2 pathway: From mechanism to medical applications

  2020cites this paper
• Chemoprevention of Cancer: Past, Present, and Future

  2020cites this paper
• The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway

  2020cites this paper
• Synthesis and Evaluation of Noncovalent Naphthalene-Based KEAP1-NRF2 Inhibitors.

  2020cites this paper
• A pathway coordinated by DELE1 relays mitochondrial stress to the cytosol

  2020cites this paper
• Therapeutic Effects of Nrf2 Activation by Bardoxolone Methyl in Chronic Heart Failure

  2019cites this paper
• Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages

  2019cites this paper
• The role of nuclear factor erythroid-2-related factor 2 expression in radiocontrast-induced nephropathy

  2019cites this paper
• Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators.

  2019cites this paper
• Identification of a Novel Hybridization from Isosorbide 5-Mononitrate and Bardoxolone Methyl with Dual Activities of Pulmonary Vasodilation and Vascular Remodeling Inhibition on Pulmonary Arterial Hypertension Rats.

  2018cites this paper
• Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach

  2018cites this paper
• Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade Signaling

  2018cites this paper
• Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.

  2018cites this paper
• Regulation of stress signaling pathways by nitro-fatty acids.

  2018cites this paper
• C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape

  2018cites this paper
• Deconvoluting Stress-Responsive Proteostasis Signaling Pathways for Pharmacologic Activation using Targeted RNA-sequencing

  2018cites this paper
• CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells

  2017cites this paper
• Differential regulation of innate immune cytokine production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn patient immune cells and monocytes

  2017cites this paper
• A bifurcated signaling cascade of NIMA-related kinases controls distinct kinesins in anaphase

  2017cites this paper
• Triterpenoid-rich loquat leaf extract induces growth inhibition and apoptosis of pancreatic cancer cells through altering key flux ratios of glucose metabolism

  2017cites this paper
• Novel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy.

  2017cites this paper
• A bifurcated signaling cascade of NIMA-related kinases controls distinct kinesins in anaphase

  2017cites this paper
• Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives.

  2017cites this paper
• Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses

  2017cites this paper
• A bifurcated signaling cascade of NIMA-related kinases controls distinct kinesins in anaphase

  2017cites this paper
• Activation of anti-oxidant Nrf2 signaling by substituted trans stilbenes.

  2017cites this paper
• Dimethyl fumarate inhibits osteoclasts via attenuation of reactive oxygen species signalling by augmented antioxidation

  2017cites this paper
• Predictive Biomarkers for Linking Disease Pathology and Drug Effect.

  2016cites this paper
• Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.

  2016cites this paper
• Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites.

  2016cites this paper
• Dietary Phytochemicals and Cancer Chemoprevention: A Perspective on Oxidative Stress, Inflammation, and Epigenetics.

  2016cites this paper
• Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis

  2016cites this paper
• Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention.

  2015cites this paper
• Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators.

  2015cites this paper
• The role of heme oxygenase in metastatic melanoma tumorigenicity

  2015influential citation
• [Synthesis and Anticancer Activity of Betulonic Acid Imidazolides].

  2015cites this paper
• Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers.

  2015cites this paper
• A systems pharmacology approach to discovery of drugs to ameliorate oxidant stress in human endothelial cells

  2015cites this paper
• Synthesis and the antineoplastic activity of imidazolides of betulonic acid

  2015cites this paper
• Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway.

  2015cites this paper
• Environmental Mycobiome Modifiers of Inflammation and Fibrosis in Systemic Sclerosis

  2015cites this paper
• Induction of Heme Oxygenase I (HMOX1) by HPP-4382: A Novel Modulator of Bach1 Activity

  2014cites this paper
• Heme Oxygenase-1 As a Target for Drug Discovery

  2014cites this paper
• Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties

  2014cites this paper
• Review of genes and results for degenerative and immunological disorders pertaining to Nrf 2 Nrf 2 target genes

  2014cites this paper
• Molecular investigation of Keap1-dependent regulation of the Nrf2 cell defence pathway

  2014cites this paper
• Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.

  2014cites this paper
• Prevention of Murine Lupus Nephritis by Targeting Multiple Signaling Axes and Oxidative Stress Using a Synthetic Triterpenoid

  2014cites this paper
• Atypical Presentations of Diabetic Nephropathy and Novel Therapies

  2014cites this paper
• Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis.

  2014cites this paper
• Reactive Oxygen Species in Inflammation and Tissue Injury

  2014cites this paper
• The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia reperfusion injury in mice

  2013cites this paper
• Bardoxolone Brings Nrf2-Based Therapies to Light

  2013cites this paper
• Pharmacological Induction of Heme Oxygenase-1 by a Triterpenoid Protects Neurons Against Ischemic Injury

  2012cites this paper
• Synthetic triterpenoids, CDDO-Imidazolide and CDDO-Ethyl amide, induce chondrogenesis.

  2012cites this paper
• NRF2 and cancer: the good, the bad and the importance of context

  2012cites this paper
• Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases

  2012cites this paper
• Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens

  2012cites this paper
• Reversible Michael additions: covalent inhibitors and prodrugs.

  2012cites this paper
• The Synthetic Triterpenoid CDDO-Methyl Ester Delays Estrogen Receptor–Negative Mammary Carcinogenesis in Polyoma Middle T Mice

  2012cites this paper